Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

66.45 +1.29 (+1.98%)
Official Closing Price Updated: 7:00 PM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
79 80 Next >
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. 
Via MarketBeat
Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug
Via The Motley Fool
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
Novo Nordisk Short
My March $115 puts on NVO​​​​​​​ are still in the green, although less so with Friday’s bounce. My faith in that well-formed H&S top is unshaken, however, so I am planning to hold on tight until the... 
Via Talk Markets
Topics Stocks / Equities
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
Despite its growth, NYSE:NVO remains within the realm of affordability.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
5 Top European Stocks to Buy Before 2025
With the U.S. stock market reaching all-time highs, it might be a good idea to check out some quality European stocks. 
Via The Motley Fool
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Novo Nordisk unveils a $1.2 billion production facility in Denmark and finalizes Catalent acquisition, with financial and operational impacts ahead. 
Via Benzinga
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Via The Motley Fool
Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study shows a low absolute risk despite significant association. 
Via Benzinga
3 Growth Stocks That Can Be No-Brainer Buys in 2025
Via The Motley Fool
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction. 
Via Benzinga
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an integrated platform with home delivery. 
Via Benzinga
2 No-Brainer Growth Stocks to Buy and Hold Through 2025 and Beyond
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
4 Stocks That Crushed Analyst Estimates by More Than Double
Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential. 
Via MarketBeat
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
Via Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Via The Motley Fool
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value. 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Via The Motley Fool
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
Salesforce and mostly positive tech earnings buoyed the major indexes. 
Via Investor's Business Daily
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies. 
Via MarketBeat
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024. 
Via Benzinga
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate. 
Via MarketBeat
Topics Government Lawsuit
Exposures Financial Legal Political
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity. 
Via Investor's Business Daily
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
79 80 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.